Introduction
============

Skin cancers are the most common primary type of cancer. The three most common primary types of cutaneous cancer are squamous cell carcinoma, basal cell carcinoma, and malignant melanoma. Melanoma is of particular interest since it tends to occur in younger adults, and has a relatively poor prognosis if metastasis has occurred.[@b1-cin-2011-121] Human epidemiological studies as well as lab animal experiments indicate that UV exposure is an important etiological factor in all three types of skin cancer.[@b2-cin-2011-121]

The spectrum of solar UV light can be divided by wavelength into UVA, UVB, and UVC. UVB spectrum light exposure is thought to explain 80%--90% of the mutagenic effects of sunlight.[@b2-cin-2011-121] DNA sequence analysis has revealed the target and effect of UVB exposure, which has come to be known as the 'UVB signature' mutation.[@b3-cin-2011-121] The targets of UVB in DNA are pyrimidine pairs containing cytosine, ie, CC, CT, or TC. Following UVB exposure, these pyrimdine pairs give rise to either C-\>T point mutations or CC-\>TT dinucleotide changes.[@b2-cin-2011-121]

The mechanism by which UVB exposure causes this pattern of mutagenesis is partially understood. UVB energy can be absorbed by pyrimidines and can result in two new intrastrand covalent bonds formed between adjacent pyrimdines.[@b4-cin-2011-121] This structure is known as a cyclobutane pyrimidine dimer (CPD). How the CPD gives rise to the observed mutations is unclear. One model supposes that a DNA polymerase introduces the incorrect nucleotide when using the CPD containing strand as the template. Another model supposes that at least one of the cytosines in the CPD are methylated and that the CPD structure increases the basal spontaneous deamination of 5-methylcytosine to thymidine.[@b2-cin-2011-121]

However, not every CPD that forms will necessarily give rise to a mutation. CPD's create a distortion in the DNA that can potentially be recognized by the nucleotide excision repair (NER) enzymes.[@b4-cin-2011-121] These enzymes can excise part of the strand flanking a CPD and use the complementary strand as a template to replace the excised sequence. The importance of this repair pathway is highlighted by Xeroderma pigmentosum patients who exhibit increased frequency of skin cancers.[@b2-cin-2011-121]

To sum up, when cells are exposed to UVB, UVB signature mutations may occur.[@b3-cin-2011-121] If these genetic alterations perturb key regulators of the cell cycle or apoptosis, skin cancer may develop. Several genetic loci have been associated with malignant melanoma including Tumor Protein 53 (TP53), Cyclin-dependent Kinase 4 (CDK4), Cyclin-dependent Kinase Inhibitor 2A (CDKN2A), Melanocortin 1 Receptor (MC1R), Microphthalmia-associated Transcription Factor (MITF), v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (KIT), v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF), Neuroblastoma RAS viral Oncogene Homolog (NRAS), B-cell Lymphoma 2 (BCL-2), Apoptotic Protease Activating Factor 1 (APAF1), v-AKT Murine Thymoma Viral Oncogene Homolog (AKT), Phosphatase and Tensin Homolog (PTEN), and FK506 Binding Protein 12-Rapamycin Associated Protein 1 (FRAP1).[@b1-cin-2011-121]

*TP53* encodes the transcriptional regulator known as p53. Following genetic damage or other cellular stresses, p53 becomes stabilized and can arrest the cell cycle or induce apoptosis.[@b5-cin-2011-121] Mutations in p53 are found in up to 5% of primary melanomas.[@b6-cin-2011-121]

CDK4 is a protein kinase that phosphorylates Retinoblastoma (Rb) to enable G1-S cell cycle progression.[@b7-cin-2011-121] Familial melanoma has been associated with lesions in CDK4.[@b8-cin-2011-121] The *CDKN2A* locus encodes two isoforms involved in melanoma, p16INK4a and p14ARF.[@b1-cin-2011-121] p16INK4a binds to CDK4 and inhibits cyclin D binding.[@b9-cin-2011-121] Binding of p14ARF with Murine Double Minute 2 (MDM2) results in stabilization of p53.[@b5-cin-2011-121] Loss-of-function mutations in *CDKN2A* cause increased CDK4 activity and a predispostion to malignant melanoma.[@b1-cin-2011-121],[@b8-cin-2011-121] Mutations in *CDK2NA* are the most common cause of familial melanoma, but can also occur sporadically.[@b1-cin-2011-121]

MC1R is a seven transmembrane G protein coupled cell surface receptor for melanocyte-stimulating hormone (MSH-alpha).[@b10-cin-2011-121] Receptor activation results in a signaling cascade resulting in expression of MITF and other genes neccesary for eumelanin synthesis.[@b11-cin-2011-121] MC1R polymorphisms are associated with melanoma.[@b12-cin-2011-121] MITF is a transcription factor that is a master regulator of melanocyte development, survival and melanogenesis.[@b13-cin-2011-121] Amplification of *MITF* has been found in melanoma.[@b14-cin-2011-121]

The tyrosine kinase KIT is required for the developmental migration and proliferation of melanocytes.[@b15-cin-2011-121] Upon binding its ligand Stem-cell Factor, KIT activates a mitogen-activated protein kinase (MAPK) signaling cascade.[@b16-cin-2011-121] Activating lesions in *KIT* have been reported in melanoma.[@b17-cin-2011-121]

NRAS is a member of the RAS family of plasma membrane bound small G proteins that can be activated by receptor tyrosine kinases.[@b18-cin-2011-121] When in its GTP bound form, RAS can activate RAF.[@b19-cin-2011-121] RAF is a protein kinase that is part of a MAPK signaling cascade that promotes cellular proliferation.[@b20-cin-2011-121] NRAS is mutated in 33% of primary melanomas, and associated with increased activity.[@b18-cin-2011-121] BRAF is mutated in about two thirds of melanomas, typically causing increased activity.[@b1-cin-2011-121]

BCL-2 is primarily found in the outer membrane of mitochondria where it acts to prevent release of apoptosis mediators from the mitochondrial intermembrane space.[@b21-cin-2011-121] The expression of BCL-2 may correlate with melanoma progression and *BCL-2* antisense therapy has been shown to increase melanoma chemosensitivity in a mouse model.[@b22-cin-2011-121],[@b23-cin-2011-121]

APAF1 forms apoptosomes with cytosolic cytochrome c.[@b24-cin-2011-121] This complex activates caspase-9, resulting in programmed cell death. *APAF1* may undergo loss of heterozygosity as well as decreased expression due to methylation in melanoma.[@b25-cin-2011-121]

*PTEN* encodes a lipid and protein phosphatase that regulates levels of phosphatidylinositol (3,4,5)-triphosphate (PIP3) by dephosphorylation.[@b26-cin-2011-121] Thus, decreased PTEN activity causes an increase in PIP3. PIP3 recruits the serine/threonine protein kinase AKT3 to the cell membrane where it is becomes activated.[@b27-cin-2011-121] Through phosphorylation of various substrates, AKT3 inhibits apoptosis.[@b27-cin-2011-121] AKT3 activity is increased in up to 60% of nonfamilial melanomas due to either increased copies of AKT3 or loss of PTEN.[@b28-cin-2011-121]

FRAP1, also known as mammalian Target of Rapamycin (mTOR), is a protein kinase that is found in two different complexes called mTORC1 and mTORC2.[@b29-cin-2011-121] mTORC1 promotes protein translation, favoring cell proliferation.[@b29-cin-2011-121] mTORC2 activates AKT by phosphorylation.[@b29-cin-2011-121] Increased mTOR activity was observed in 73% of melanomas.[@b30-cin-2011-121]

Despite the known importance of UVB sites in the etiology of skin cancers, there has been little work characterizing their distribution in the human genome. One goal of this work was to have a genome wide analysis of UVB sites with respect to coding sequences. Furthermore, we investigated the degree to which these UVB sites would be deleterious if mutated. In addition, we explored the relationship between UVB sites and genes implicated in malignant melanoma. One supposition is that these coding sequences would have an overabundance of UVB sites that may predispose them to mutation. Another possibility is that the UVB sites found in these coding sequences are present in a sequence context that is more deleterious than that of the average gene.

Finally, we propose a novel approach for genetically modifying skin cancer susceptibility. Given that UVB sites are the target of UVB mutagenesis, decreasing the frequency of these sites should decrease the susceptibility of a coding sequence to UVB mutation. We propose a method for decreasing the frequency of UVB sites while maintaining the wildtype primary amino acid sequence by the rational use of synonymous codon substitution. In this work, we bioinformatically predict the extent to which this method can improve UVB resistance of coding sequences.

Methods
=======

An algorithm was developed which first identifies potential UVB sites in human protein coding sequences, individually introduces UVB signature mutations at these sites, and then predicts the consequence to the protein product. The UVB signature target site is defined as any of the dinucleotides CC, CT, and TC (and GG, AG, and GA considering the change may occur on the complementary strand). The algorithm identifies every UVB site in translated exonic genomic sequences. In addition, UVB sites may potentially be found at the junctions of exons, therefore, when extracting an exon from genomic sequence, we also took one additional nucleotide from each side of an exon in the analysis to not miss those instances where the UVB site straddled the junction. These flanking nucleotides were trimmed after screening for UVB sites in the coding sequence.

The algorithm then individually creates a series of UVB single point mutants of the coding sequence by introducing single transition mutations (C-\>T or G-\>A) at each site. For CC and GG dinucleotide sites, there would be two separate single transition mutant sequences generated. In addition, UVB doublet mutants of coding sequences were created at dinucleotides CC (and GG considering the change may occur on the complementary strand) by introducing two transitions mutations (CC-\>TT or GG-\>AA). Doublet mutants at CC and GG dinucleotides were not created if they straddled two codons (corresponding to phase 3 position of the first codon and phase one position of the subsequent codon) because this information was already captured in the two single mutants created.

For each mutant, the BLOSUM62 amino acid substitution matrix was then used to quantitatively assess the consequence of the altered codon when translated.[@b31-cin-2011-121] BLOSUM62 uses a log odds ratio score and awards negative scores to unfavorable amino acid substitutions.[@b32-cin-2011-121] The sum score for all unfavorable mutations for a gene was computed to get an overall amino acid change score representing the UV susceptibility of the protein coding gene ([Fig. 1](#f1-cin-2011-121){ref-type="fig"}). A perl script was written to carry out this algorithm.

Version 37 of the human genome chromosomal genbank flat files were obtained for analysis (<http://www.ncbi.nlm.nih.gov/Ftp/>). A total of 32,357 coding sequences (CDS) were analyzed. 95 coding sequenes were not analyzed because they were incomplete fragments. Due to our inclusion of flanking nucleotides in screening for UVB sites, the calculation of length of a coding sequence for the purpose of estimating UVB frequency, was defined as the sum of all coding sequence nucleotides including the stop codon + 2 · (number of exons that contained coding sequence).

Genes were optimized for UVB resistance by selective synonymous codon substitution. The wildtype primary amino acid sequence was maintained but used the following codons substituted for the original codons: F = \> TTT, L = \> TTA, I = \> ATT, M = \> ATG, V = \> GTA, S = \> TCA, P = \> CCA, T = \> ACA, A = \> GCA, Y = \> TAT, STOP = \> TAA, H = \> CAT, Q = \> CAA, N = \>AAT,K = \> AAA, D = \> GAT, E = \> GAA, C = \> TGT, W = \> TGG, R = \> CGT, G = \> GGT.

GC percentage, length, and dinucleotide composition were calculated for each coding sequence. The output from the perl script was parsed into an Excel spreadsheet for ease of viewing. The data was imported into R for statistical analysis using the Bioconductor package multtest.[@b33-cin-2011-121],[@b34-cin-2011-121] *P* values were corrected for multiple measures using the Benjamini and Hochberg method.[@b35-cin-2011-121] Mean GC percentage was calculated as the arithmetic mean of each CDS GC percentage.

Chi squared tests were used to estimate *P* values for observed number of UVB sites per CDS, as well as for observed frequency of UVB sites that were deleterious. The expected number of UVB signature sites was calculated as the product of (0.3918 or 0.445)· (length of CDS in nucleotides(nt) −1). The number 0.3918 is the probability of a dinucleotide being a UVB site based on a 53.48% GC composition and random distribution. The number 0.445 is the probability of a dinucleotide being a UVB site based on the average UVB frequency among all coding sequences. The number of dinucleotides in a single stranded sequence is equal to the length in nt minus one.

The expected number of deleterious single mutation sites in a CDS was calculated by multiplying the number of UVB sites in each CDS by 0.298. The number 0.298 is the mean frequency of a single mutation being deleterious among all coding sequences.

The expected number of deleterious double mutation sites in a CDS was calculated by multiplying the number of CC and GG UVB sites by 0.679. The number 0.679 is the mean frequency of a double mutation being deleterious among all coding sequences.

To analyze average severity of single deleterious mutations, a control sample of the first 65000 negative BLOSUM62 single amino acid scores were collected from chromosome 5, which had a mean of −2.14. This set of scores was used for comparison of the single mutation negative scores from each melanoma related coding sequence two tailed Student's t-test with equal variances.

Results
=======

We investigated the frequency of UVB sites in human coding sequences. At the outset, we expected UVB sites to be found 3/8 (or 38.75%) of the time for any dinucleotide of sequence considered. This assumption was based on probability with equal frequency (25%) of the four nucleotides. This expectation was modified based on the average GC composition of the coding sequences of 53.48% to arrive at a 39.18% frequency of a UVB site at any given dinucleotide to be expected by chance. Interestingly, the observed mean frequency of UVB dinucleotides among all coding sequences was 44.5% ± 5.2%, which was significantly greater than expected (*P* \< 2.2E-16).

On average, only about 30% of the potential single transitions would result in an unfavorable amino acid substitution ([Table 1](#t1-cin-2011-121){ref-type="table"}). Considering doublet UVB mutations at positions 1--2 or 2--3 of codons, about 68% of these would give rise to unfavorable amino acid changes. Unfavorable mutations at doublet sites also tended to be more deleterious substitutions with a mean BLOSUM62 score of −2.69 per residue change compared to −2.16 at single unfavorable sites.

The number of UVB sites in human coding sequences could be important for susceptibility to UVB mutagenesis. We counted the number of UVB sites in human coding sequences and observed that the number increases linearly as a function of the length of the coding sequence (R^2^ = 0.988) ([Fig. 2](#f2-cin-2011-121){ref-type="fig"}). In addition, based on our model, the calculated amino acid change score grows more negative in a linear fashion with respect to length (R^2^ = −0.939) (data not shown). Thus, longer open reading frames are predicted to be more susceptible to UVB. However, neither the number of UVB sites nor the amino acid change score correlated with the GC percentage of the coding sequence (R^2^ = −0.005 and R^2^ = −0.063) (data not shown).

We investigated whether genes associated with malignant melanoma would have a signficantly different number of UVB sites than would be expected from the average frequency of UVB sites. Seven of the genes had significantly fewer than expected UVB sites, while four were not significantly different from the average gene. One isoform of CDK2NA was found to have a significantly increased number of UVB sites ([Table 2](#t2-cin-2011-121){ref-type="table"}).

It could be that a greater proportion of the UVB sites in genes implicated in malignant melanoma could give rise to deleterious substitutions if mutated. The predicted proportion of UVB site mutations causing a deleterious change was evaluated in the genes linked to malignant melanoma ([Tables 3](#t3-cin-2011-121){ref-type="table"} and [4](#t4-cin-2011-121){ref-type="table"}). A subset of those coding sequences did have a significantly increased proportion of sites predicted to produce unfavorable changes, including four of seven coding sequences from *TP53*, one of the *CDK2NA* isoforms and *BRAF. FRAP1* had a smaller proportion of sites that were unfavorable.

We studied whether the UVB sites in coding sequences of genes implicated in melanoma would on average cause more deleterious changes than those found in the average coding sequence. This would be reflected by more negative BLOSUM62 scores. The predicted mean severity of UVB deleterious mutations was compared in genes linked to melanoma and a large control group ([Table 5](#t5-cin-2011-121){ref-type="table"}). Mutations at UVB sites in the coding sequences of *APAF1* and *FRAP1* were predicted to be significantly more deleterious.

Finally, we explored the use of rational synonymous codon substitution to alter the coding sequence without changing the primary amino acid sequence in order to decrease the predicted vulnerability to UVB ([Table 6](#t6-cin-2011-121){ref-type="table"}). This method was found to decrease the number of UVB sites by almost 50% and improve the amino acid change score for the coding sequences of all genes associated with malignant melanoma by about 25%.

Discussion
==========

Despite the importance of UVB sites in skin cancer formation, the extent of these targets and their potential for deleterious mutations has not been previously investigated on a genome-wide basis. We found that these sites are quite prevalent in human coding sequences and are predicted to have signficant deleterious potential. However, it was suprising that the majority of the time, the predicted consequence of any one single transition mutation at a UVB site is not unfavorable. It is interesting to note that the average coding sequence has more UVB sites than would be expected at random. This may be a consequence of codon usage biases or it may reflect an adaptive mechanism to facilitate UVB molecular mutation.

As UVB is a major causative factor in skin cancer and leads to UVB signature mutations, we hypothesized that the sequence properties of genes may influence their likelihood to suffer from UVB induced loss of function mutations. That is, certain genes would have sequences that either contain more UVB targets or the targets tend to occur in a more sensitive context that would lead to unfavorable mutations in either greater frequency or severity or some combination thereof. Surprisingly, most genes associated with melanoma have a fewer than expected number of UVB sites. This may reflect a selective process for these genes to avoid UVB mutagenesis. However, our data suggests that all three mechanisms may be at play depending on the coding sequence. Some coding sequences have an increased number of UVB sites, some have an increased frequency of UVB sites that are deleterious and some tend to have more deleterious changes on average when mutated. These qualities may be useful in screening for additional genes important in melanoma, to identify additional diagnostic and therapeutic molecular targets.

Metastatic melanoma is associated with a 10 year survival rate of less than 10%.[@b36-cin-2011-121] In addition, the frequency of melanoma is increasing and over 60,000 new cases occur each year in the United States.[@b37-cin-2011-121] Therefore, the need for new methods for primary prevention of melanoma or in its treatment are greater than ever. We have described a new method for decreasing the susceptibility of coding sequences to UV, much like sunscreen for genes. Although currently preclinical, cutaneous gene therapy has promise.[@b38-cin-2011-121] As gene therapy advances, genetically engineering decreased vulnerability of a gene to UVB may be useful therapeutically in the treatment of this devastating disease.

Supplementary Data
==================

Collection of output files from perl script are available at <http://bengal.missouri.edu/kale0a>.

Perl script: Mel15.pl.

Excel file of data in a tabular format: mel_table.xls.
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![Schematic representation of algorithm to assess UVB sensitivity. At left, boxes are drawn around UVB sites. Below the double stranded DNA is the single letter amino acid sequence for each codon of the upper strand. In the middle, nucleotides that have undergone mutation are shown in bold. The translated sequence is shown below the DNA. The BLOSUM62 substitution matrix score for each new amino acid compared to its original amino acid is shown at the bottom. At right, the sum of the negative BLOSUM62 scores is given as the total amino acid change score for this sequence.](cin-2011-121f1){#f1-cin-2011-121}
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###### 

UVB characteristics of human coding sequences.

  ------------------------------------------------------------------------ --------------
  Mean % of dinucleotides that are UVB sites (±SD)                         44.5% ± 5.2%
  Mean % of UVB sites with single nt changes that were deleterious (±SD)   29.8 ± 5.8
  Mean % of UVB sites with double nt changes that were deleterious (±SD)   67.9 ± 8.5
  Mean amino acid change score per single nt deleterious mutation (±SD)    −2.16 ± 0.14
  Mean amino acid change score per double nt deleterious mutation (±SD)    −2.69 ± 0.21
  ------------------------------------------------------------------------ --------------

###### 

Analysis of UVB site frequencies in the coding sequences of genes implicated in malignant melanoma.

  **Gene**   **Protein**      **Observed**   **Expected**   ***P* value**
  ---------- ---------------- -------------- -------------- ---------------
  *FRAP1*    NP_004949.1      3344           3403.8         0.236
  *NRAS*     NP_002515.1      204            253.21         *1.22E-04*
  *AKT3*     NP_859029.1      535            621.66         *1.38E-05*
  *AKT3*     NP_005456.1      559            640.36         *6.22E-05*
  *MITF*     NP_937802.1      647            695.09         *2.80E-02*
  *MITF*     NP_006713.1      643            693.75         *1.98E-02*
  *MITF*     NP_937820.1      623            673.73         *1.81E-02*
  *MITF*     NP_937821.1      605            661.72         *7.20E-03*
  *MITF*     NP_000239.1      504            560.25         *3.62E-03*
  *MITF*     NP_937801.1      500            552.25         *6.70E-03*
  *KIT*      NP_000213.1      1122           1303.85        *1.53E-10*
  *KIT*      NP_001087241.1   1120           1298.51        *3.11E-10*
  *BRAF*     NP_004324.2      924            1023.5         *1.11E-04*
  *CDKN2A*   NP_000068.1      217            209.15         0.550
  *CDKN2A*   NP_478102.1      242            231.84         0.456
  *CDKN2A*   NP_478104.2      186            155.75         *2.96E-03*
  *PTEN*     NP_000305.3      417            538.89         *2.32E-11*
  *CDK4*     NP_000066.1      421            405.39         0.381
  *APAF1*    NP_863651.1      1425           1666.97        *3.56E-14*
  *APAF1*    NP_863658.1      1378           1609.57        *1.70E-13*
  *APAF1*    NP_037361.1      1415           1652.29        *8.82E-14*
  *APAF1*    NP_001151.1      1368           1594.88        *4.13E-13*
  *APAF1*    NP_863659.1      404            452.12         *5.73E-03*
  *TP53*     NP_001119584.1   562            525.54         0.0576
  *TP53*     NP_000537.3      562            525.54         0.0576
  *TP53*     NP_001119587.1   365            349.32         0.340
  *TP53*     NP_001119585.1   476            462.8          0.495
  *TP53*     NP_001119589.1   279            286.58         0.626
  *TP53*     NP_001119586.1   471            456.12         0.435
  *TP53*     NP_001119588.1   274            279.91         0.707
  *BCL2*     NP_000624.2      345            319.95         0.0978
  *BCL2*     NP_000648.2      296            274.56         0.128

###### 

Frequency of single site UVB mutations being deleterious in the coding sequences of genes implicated in malignant melanoma.

  **Gene**   **Protein**      **Observed**   **Expected**   ***P* value**
  ---------- ---------------- -------------- -------------- ---------------
  *FRAP1*    NP_004949.1      812            978.63         *4.69E-09*
  *NRAS*     NP_002515.1      47             59.3           0.124
  *AKT3*     NP_859029.1      147            133.8          0.292
  *AKT3*     NP_005456.1      150            139.17         0.410
  *MITF*     NP_937802.1      175            185.36         0.505
  *MITF*     NP_006713.1      171            182.38         0.454
  *MITF*     NP_937820.1      165            177.31         0.406
  *MITF*     NP_937821.1      164            173.44         0.533
  *MITF*     NP_000239.1      135            143.34         0.547
  *MITF*     NP_937801.1      133            142.15         0.501
  *KIT*      NP_000213.1      317            302.77         0.470
  *KIT*      NP_001087241.1   316            302.17         0.484
  *BRAF*     NP_004324.2      311            254.49         *1.93E-04*
  *CDKN2A*   NP_000068.1      60             75.99          0.0719
  *CDKN2A*   NP_478102.1      105            81.95          *9.62E-03*
  *CDKN2A*   NP_478104.2      62             57.22          0.588
  *PTEN*     NP_000305.3      112            108.17         0.764
  *CDK4*     NP_000066.1      123            122.48         0.972
  *APAF1*    NP_863651.1      368            365.35         0.915
  *APAF1*    NP_863658.1      356            350.45         0.813
  *APAF1*    NP_037361.1      362            362.37         0.988
  *APAF1*    NP_001151.1      350            347.47         0.916
  *APAF1*    NP_863659.1      106            101.02         0.678
  *TP53*     NP_001119584.1   193            163.01         *1.79E-02*
  *TP53*     NP_000537.3      193            163.01         *1.79E-02*
  *TP53*     NP_001119587.1   112            106.98         0.686
  *TP53*     NP_001119585.1   171            138.57         *4.73E-03*
  *TP53*     NP_001119589.1   90             82.55          0.468
  *TP53*     NP_001119586.1   170            137.38         *4.28E-03*
  *TP53*     NP_001119588.1   89             81.35          0.451
  *BCL2*     NP_000624.2      115            111.45         0.785
  *BCL2*     NP_000648.2      103            97.15          0.613

###### 

Frequency of deleterious double site UVB mutations in the coding sequences of genes implicated in malignant melanoma.

  **Gene**   **Protein**      **Observed**   **Expected**   ***P* value**
  ---------- ---------------- -------------- -------------- ---------------
  *FRAP1*    NP_004949.1      374            406.04         *0.0483*
  *NRAS*     NP_002515.1      20             23.77          0.41952
  *AKT3*     NP_859029.1      57             53.64          0.66931
  *AKT3*     NP_005456.1      60             56.36          0.6467
  *MITF*     NP_937802.1      97             86.23          0.18206
  *MITF*     NP_006713.1      90             82.16          0.35182
  *MITF*     NP_937820.1      89             80.8           0.31838
  *MITF*     NP_937821.1      89             80.8           0.31838
  *MITF*     NP_000239.1      70             63.83          0.41952
  *MITF*     NP_937801.1      68             62.47          0.47403
  *KIT*      NP_000213.1      143            136.48         0.58688
  *KIT*      NP_001087241.1   143            135.8          0.5377
  *BRAF*     NP_004324.2      130            124.94         0.67396
  *CDKN2A*   NP_000068.1      30             40.74          0.03377
  *CDKN2A*   NP_478102.1      51             55.68          0.5311
  *CDKN2A*   NP_478104.2      34             35.99          0.77353
  *PTEN*     NP_000305.3      46             40.74          0.38021
  *CDK4*     NP_000066.1      59             57.72          0.89452
  *APAF1*    NP_863651.1      136            126.97         0.39808
  *APAF1*    NP_863658.1      131            122.22         0.40319
  *APAF1*    NP_037361.1      135            125.62         0.37138
  *APAF1*    NP_001151.1      130            120.86         0.37571
  *APAF1*    NP_863659.1      46             40.74          0.38021
  *TP53*     NP_001119584.1   107            92.34          0.05998
  *TP53*     NP_000537.3      107            92.34          0.05998
  *TP53*     NP_001119587.1   64             57.04          0.31334
  *TP53*     NP_001119585.1   92             79.44          0.08774
  *TP53*     NP_001119589.1   49             44.14          0.44857
  *TP53*     NP_001119586.1   92             79.44          0.08774
  *TP53*     NP_001119588.1   49             44.14          0.44857
  *BCL2*     NP_000624.2      65             68.58          0.69252
  *BCL2*     NP_000648.2      58             61.11          0.72115

###### 

Mean severity of deleterious single mutations in the coding sequences of genes implicated in malignant melanoma.

  **Gene**   **Protein**      **Mean severity**   ***P* value**
  ---------- ---------------- ------------------- ---------------
  *FRAP1*    NP_004949.1      −2.33               *8.96E-05*
  *NRAS*     NP_002515.1      −1.98               0.682
  *AKT3*     NP_859029.1      −2.23               0.738
  *AKT3*     NP_005456.1      −2.21               0.831
  *MITF*     NP_937802.1      −2.05               0.682
  *MITF*     NP_006713.1      −2.02               0.549
  *MITF*     NP_937820.1      −2.05               0.682
  *MITF*     NP_937821.1      −2.07               0.750
  *MITF*     NP_000239.1      −2.04               0.682
  *MITF*     NP_937801.1      −2.04               0.682
  *KIT*      NP_000213.1      −2.1                0.831
  *KIT*      NP_001087241.1   −2.1                0.831
  *BRAF*     NP_004324.2      −2.16               0.969
  *CDKN2A*   NP_000068.1      −2.15               0.979
  *CDKN2A*   NP_478102.1      −2.03               0.682
  *CDKN2A*   NP_478104.2      −2.19               0.960
  *PTEN*     NP_000305.3      −2.16               0.979
  *CDK4*     NP_000066.1      −2.2                0.831
  *APAF1*    NP_863651.1      −2.34               *3.49E-03*
  *APAF1*    NP_863658.1      −2.35               *2.56E-03*
  *APAF1*    NP_037361.1      −2.35               *2.56E-03*
  *APAF1*    NP_001151.1      −2.36               *2.56E-03*
  *APAF1*    NP_863659.1      −2.32               0.386
  *TP53*     NP_001119584.1   −2.13               0.979
  *TP53*     NP_000537.3      −2.13               0.979
  *TP53*     NP_001119587.1   −2.11               0.965
  *TP53*     NP_001119585.1   −2.14               0.995
  *TP53*     NP_001119589.1   −2.11               0.969
  *TP53*     NP_001119586.1   −2.14               0.979
  *TP53*     NP_001119588.1   −2.1                0.965
  *BCL2*     NP_000624.2      −2.2                0.831
  *BCL2*     NP_000648.2      −2.2                0.831

###### 

Synonymous codon substitution can decrease predicted UVB vulnerability of genes implicated in malignant melanoma.

  **Gene**   **Protein**      **WT UVB sites**   **WT score**   **Optimized UVB sites**   **Optimized score**
  ---------- ---------------- ------------------ -------------- ------------------------- ---------------------
  *FRAP1*    NP_004949.1      3284               −2874          1464                      −2096
  *NRAS*     NP_002515.1      199                −137           108                       −105
  *AKT3*     NP_859029.1      449                −487           261                       −355
  *AKT3*     NP_005456.1      467                −497           274                       −361
  *MITF*     NP_937802.1      622                −612           305                       −466
  *MITF*     NP_006713.1      612                −582           295                       −449
  *MITF*     NP_937820.1      595                −574           288                       −444
  *MITF*     NP_937821.1      582                −575           284                       −449
  *MITF*     NP_000239.1      481                −460           239                       −358
  *MITF*     NP_937801.1      477                −449           236                       −351
  *KIT*      NP_000213.1      1016               −1058          558                       −789
  *KIT*      NP_001087241.1   1014               −1057          556                       −788
  *BRAF*     NP_004324.2      854                −1029          511                       −795
  *CDKN2A*   NP_000068.1      255                −217           120                       −151
  *CDKN2A*   NP_478102.1      275                −349           157                       −258
  *CDKN2A*   NP_478104.2      192                −226           108                       −159
  *PTEN*     NP_000305.3      363                −372           225                       −311
  *CDK4*     NP_000066.1      411                −445           204                       −302
  *APAF1*    NP_863651.1      1226               −1217          694                       −931
  *APAF1*    NP_863658.1      1176               −1183          668                       −909
  *APAF1*    NP_037361.1      1216               −1205          685                       −923
  *APAF1*    NP_001151.1      1166               −1171          659                       −901
  *APAF1*    NP_863659.1      339                −364           200                       −250
  *TP53*     NP_001119584.1   547                −715           293                       −516
  *TP53*     NP_000537.3      547                −715           293                       −516
  *TP53*     NP_001119587.1   359                −402           174                       −268
  *TP53*     NP_001119585.1   465                −639           258                       −485
  *TP53*     NP_001119589.1   277                −326           139                       −237
  *TP53*     NP_001119586.1   461                −633           258                       −479
  *TP53*     NP_001119588.1   273                −320           139                       −231
  *BCL2*     NP_000624.2      374                −427           175                       −295
  *BCL2*     NP_000648.2      326                −381           160                       −262
